The multicenter clinical-epidemioilogical program "CALIPSO" included 4865 patients with chronic cerebrovascular insufficiency associated with arterial hypertension. Patients received cavinton in intravenous infusions in drops during one week in dosage (25 mg in the 1-4 days, 50 mg in the 5-7 days) and then perorally in dose 30 mg/day during 90 days. The data analysis of the first 1011 individual medical records revealed the significant decrease of patient's complaints (p<0,001) and severity of neurological symptoms (p<0,05) as well as the improvement in scores on the Tinnetti scale (p<0,001) and the MMSE (p<0,001). The safety profile of the drug was confirmed.